Jade Biosciences, Inc. Net Fee Amt
Jade Biosciences, Inc. (JBIO) had Net Fee Amt of $5.70 thousand as of 2026-05-07, per its S-8 filed 2026-05-07.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-05-07
- 2026-05-07: Net Fee Amt $5.70K.
- 2026-05-06: Net Fee Amt $67.63K.
- 2026-05-04: Net Fee Amt $82.86K.
| Period end | Net Fee Amt |
|---|---|
| 2026-05-07 | $5.70K S-8 · filed 2026-05-07 |
| 2026-05-06 | $67.63K S-3 · filed 2026-05-07 |
| 2026-05-04 | $82.86K S-3 · filed 2026-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |